Turning the tide: Braf-targeted therapy enabling surgical downstaging in stage ivc anaplastic thyroid cancer

Introduction: Anaplastic thyroid cancer (ATC) constitutes less than 2% of thyroid cancer but accounts for up to 50% of thyroid cancer mortality, with a median survival of 3–6 months. All ATC is Stage IV at diagnosis by definition. BRAF V600E-mutant disease is the only molecularly defined subset with FDA-approved targeted therapy (dabrafenib–trametinib). We report a case in which BRAF-directed therapy enabled curative-intent surgery in a patient with Stage IVC disease. Case Report: A 68-year-old woman presented with a rapidly enlarging right thyroid mass, facial plethora and internal jugular vein thrombosis. Core biopsy and immunohistochemistry confirmed ATC; next-generation sequencing revealed a BRAF V600E, TERT promoter and TP53 “triple-hit” signature arising from a dedifferentiated papillary carcinoma. PET-CT showed an FDG-avid primary, nodal disease and bilateral lung metastases (Stage IVC). She received palliative external beam radiotherapy and chemotherapy, followed by dabrafenib plus trametinib, achieving a 70% partial response with resolution of nodal and pulmonary disease. Disease progression eight months later prompted addition of pembrolizumab, complicated by immune-related granulomatous panniculitis requiring discontinuation. Multidisciplinary review subsequently confirmed an isolated thyroid remnant with no residual nodal or distant disease, permitting total thyroidectomy with bilateral neck dissection. Results and Conclusion: Histopathology confirmed unifocal ATC with 40% treatment response, a 1 mm ancestral papillary carcinoma focus, and involved margins; disease was restaged as ypT3bN1a (Stage IVA). The patient is euthyroid on levothyroxine, receiving adjuvant radiotherapy, with BRAF-targeted therapy to resume thereafter with three-monthly surveillance imaging. This case shows that BRAF-directed dual MAPK blockade can downstage unresectable, metastatic ATC to resectable disease, transforming outcomes in a malignancy once regarded as fatal. Early BRAF testing and multidisciplinary care are essential to enable this therapeutic paradigm shift.